Brought to you by 
Celera acquires Axys Pharmaceuticals
21 Jun 2001
Executive Summary
Applera's Celera Genomics acquired medicinal and structural chemistry company Axys Pharmaceuticals for $174mm in Celera stock. The deal values each Axys share at $4.65, a 35% premium over the pre-announcement closing price, and involves a collar provision.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celera acquires Axys Pharmaceuticals
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice